Asparagine endopeptidase cleaves tau at N167 after uptake into microglia.


Journal

Neurobiology of disease
ISSN: 1095-953X
Titre abrégé: Neurobiol Dis
Pays: United States
ID NLM: 9500169

Informations de publication

Date de publication:
10 2019
Historique:
received: 22 03 2019
revised: 08 06 2019
accepted: 19 06 2019
pubmed: 24 6 2019
medline: 25 3 2020
entrez: 24 6 2019
Statut: ppublish

Résumé

Tau cleavage by different proteolytic enzymes generates short, aggregation-prone fragments that have been implicated in the pathogenesis of Alzheimer's disease (AD). Asparagine endopeptidase (AEP) activity in particular has been associated with tau dysfunction and aggregation, and the activity of the protease is increased in both aging and AD. Using a mass spectrometry approach, we identified a novel tau cleavage site at N167 and confirmed its processing by AEP. In combination with the previously known site at N368, we show that AEP cleavage yields a tau fragment that is present in both control and AD brains at similar levels. AEP is a lysosomal enzyme, and our data suggest that it is expressed in microglia rather than in neurons. Accordingly, we observe tau cleavage at N167 and N368 after endocytotic uptake into microglia, but not neurons. However, tau

Identifiants

pubmed: 31229689
pii: S0969-9961(19)30176-7
doi: 10.1016/j.nbd.2019.104518
pii:
doi:

Substances chimiques

tau Proteins 0
Cysteine Endopeptidases EC 3.4.22.-
asparaginylendopeptidase EC 3.4.22.34

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

104518

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Annika Behrendt (A)

BioMed X Innovation Center, Im Neuenheimer Feld 515, Heidelberg 69120, Germany.

Maria Bichmann (M)

BioMed X Innovation Center, Im Neuenheimer Feld 515, Heidelberg 69120, Germany.

Ebru Ercan-Herbst (E)

BioMed X Innovation Center, Im Neuenheimer Feld 515, Heidelberg 69120, Germany.

Per Haberkant (P)

European Molecular Biology Laboratory (EMBL), Meyerhofstraße 1, Heidelberg 69117, Germany.

David C Schöndorf (DC)

BioMed X Innovation Center, Im Neuenheimer Feld 515, Heidelberg 69120, Germany.

Michael Wolf (M)

BioMed X Innovation Center, Im Neuenheimer Feld 515, Heidelberg 69120, Germany.

Salma A Fahim (SA)

BioMed X Innovation Center, Im Neuenheimer Feld 515, Heidelberg 69120, Germany.

Enrico Murolo (E)

BioMed X Innovation Center, Im Neuenheimer Feld 515, Heidelberg 69120, Germany.

Dagmar E Ehrnhoefer (DE)

BioMed X Innovation Center, Im Neuenheimer Feld 515, Heidelberg 69120, Germany. Electronic address: ehrnhoefer@bio.mx.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH